> Membres > Chercheurs associés

Chercheurs associés

LE CŒUR Sophie

Démographe-Épidémiologiste, Directrice de recherche, INED.
Elle a été chercheur puis chercheur associé au Ceped

Courriel : lecoeur chez ined.fr

Champs de recherche : Infection à VIH, prévention, santé maternelle et infantile, Asie du Sud-Est, morbidité, mortalité, Adolescents, qualité de vie, coût-efficacité.

Zones géographiques étudiées : Asie et Océanie.

Publications

  • Amzal Billy, Jourdain Gonzague, Cressey Tim R., Ngo-Giang-Huong Nicole, Le Cœur Sophie, Boonrod Kamol, Santadusit Sadhit, Jarupanich Tapnarong, Achalapong Jullapong, Ngampiyasakul Chaiwat et Lallemant Marc (2011) « Maternal and infant nevirapine for the prevention of mother-to-child transmission of HIV in women with <8 weeks of prenatal HAART: a Bayesian analysis » (communication orale), présenté à Third International Workshop on HIV Pediatrics, Rome.

  • Briand Nelly, Le Cœur Sophie, Jourdain Gonzague, Hotrawarikarn Somboon, Sirinontakan Surat, Hinjiranandana Temsiri, Kanjanavanit Suparat, Traisathit Patrinee, McIntosh Kenneth et Lallemant Marc (2010) « Hematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand », AIDS Res Hum Retroviruses, 26, p. 1163-6. DOI : 10.1089/aid.2010.0034.
    Résumé : The evolution of hematological parameters in HIV-1-exposed uninfected infants according to various durations of perinatal zidovudine exposure was studied. We used data prospectively collected among 1122 HIV-uninfected formula-fed infants born to HIV-infected mothers who participated in a clinical trial to prevent perinatal transmission in Thailand (PHPT-1). Infants were exposed to different durations of zidovudine both in utero and after birth. Hemoglobin level and leukocyte, absolute neutrophil, and lymphocyte counts were measured at birth and at 6 weeks of age. The association between hematological parameters at birth and the duration of zidovudine exposure in utero was studied using a linear regression model, and changes between birth and 6 weeks of age and the duration of postnatal zidovudine exposure using mixed effects models. At birth, the hemoglobin level was lower in newborns exposed to zidovudine for more than 7.5 weeks in utero (adjusted regression coefficient: -0.6 g/dl; 95% confidence interval: -1.1 to -0.1). Six weeks after birth, the hemoglobin level had decreased faster in infants administered zidovudine for more than 4 weeks (adjusted regression coefficient: -0.1 g/dl; 95% confidence interval: -0.2 to -0.1). The duration of perinatal zidovudine exposure was not associated with the evolution of leukocyte, neutrophil, and lymphocyte counts. Despite the differences in hemoglobin levels, grade 3 or 4 anemia did not significantly differ by maternal or infant zidovudine duration. The clinical impact appeared modest, but longer exposure may warrant close monitoring.
    Mots-clés : Anemia/chemically induced, Confidence Intervals Drug Monitoring Female HIV Infections, drug therapy Randomized Controlled Trials as Topic, drug therapy/prevention & control/transmission HIV-1, pathogenicity Hematologic Tests Humans Infant Infant, Newborn Infectious Disease Transmission, Vertical, Pregnancy Complications, Infectious, prevention & control Linear Models Neutropenia/chemically iinduced Neutrophils/virology Pregnancy, Thailand, Zidovudine/ therapeutic use.
  • Briand Nelly, Le Cœur Sophie, Jourdain Gonzague, Hotrawarikarn Somboon, Sirinontakan Surat, Hinjiranandana Temsiri, Kanjanavanit Suparat, Traisathit Patrinee, McIntosh Kenneth, Lallemant Marc et Program for HIV Prevention and Treatment (PHPT) (2011) « Haematological Safety of Perinatal Exposure to Zidovudine in Uninfected Infants Born to HIV-1 Infected Women in Thailand » (poster), présenté à 13th National AIDS Seminar "AIDS Rights is Human Rights, Join to Protect and Respond", Nonthaburi.
  • Briand Nelly, Pornprasert Sakorn, Ngo-Giang-Huong Nicole, Galacteros Fréderic, Pissard Serge, Tatu Thanusak, Sanguansermsri Torpong, Jourdain Gonzague, Lallemant Marc et Le Cœur Sophie (2009) « Perinatal zidovudine prophylaxis in HIV type-1-infected pregnant women with thalassaemia carriage in Thailand », Antivir Ther, 14, p. 117-22.
    Résumé : BACKGROUND: To investigate a possible interaction between alpha-thalassaemia, beta-thalassaemia and haemoglobin-E trait and the haematological parameters of HIV type-1 (HIV-1)-infected pregnant women receiving zidovudine prophylaxis for the prevention of mother-to-child HIV-1 transmission in Thailand. METHODS: The study sample was composed of HIV-1-infected pregnant women receiving zidovudine (300 mg twice daily) from 28 weeks of gestational age to delivery as part of the Perinatal HIV Prevention Trial (PHPT-1), a large trial investigating zidovudine use in pregnancy. These women were randomly selected and screened for haemoglobin abnormalities. Haemoglobin levels, haematocrit and erythrocyte, leukocyte, absolute neutrophil and absolute lymphocyte counts were measured at 26, 32 and 35 weeks of gestation and at delivery. PCR genotyping techniques were used to screen for haemoglobin abnormalities, which included alpha-thalassaemia-1 Southeast Asian type deletion, beta-thalassaemia mutation (codons 41/42 [-TCTT], codon 17 [A-->T], intervening sequence-I nucleotide 1 [G-->T], codons 71/72 [+A]) and haemoglobin-E trait. The evolution of haematological parameters between 26 weeks and delivery was compared according to thalassaemia carriage using linear mixed models adjusted for baseline sociodemographic characteristics, HIV clinical stage, CD4+ T-cell count and viral load. RESULTS: At baseline, women with thalassaemia or haemoglobin-E trait had significantly lower haemoglobin level and red blood cell counts than women with no haemoglobin abnormalities, whereas absolute neutrophil and leukocyte counts were significantly higher. Exposure to zidovudine until delivery did not increase this difference. CONCLUSIONS: Zidovudine exposure did not appear to have increased haematological toxicity in HIV-1-infected pregnant women with thalassaemia.
    Mots-clés : Administration, administration & dosage, adverse effects alpha-Thalassemia/blood, adverse effects Blood Cell Count Dna Double-Blind Method Drug Administration Schedule, blood, chemically induced Anti-HIV Agents, drug therapy, Female HIV Infections, genetics beta-Thalassemia/ blood/genetics, genetics Humans Infant, Hematologic Pregnancy Complications, Infectious, Newborn Infectious Disease Transmission, Oral Anemia, Pregnancy Complications, Thailand, transmission Hiv-1 Hemoglobin E, Vertical Mutation Pregnancy, Zidovudine/administration & dosage.
  • Cailhol Johann, Jourdain Gonzague, Le Cœur Sophie, Traisathit Patrinee, Boonrod Kamol, Prommas Sinart, Putiyanun Chaiwat, Kanjanasing Annop, Lallemant Marc et Perinatal HIV Prevention Trial Group (2009) « Association of Low CD4 Cell Count and Intrauterine Growth Retardation in Thailand », J Acquir Immune Defic Syndr, 50 (4), p. 409-413.
  • Chanthavilay Phetsavanh, Ariyadej Surabon, Halue Guttiga, Chaiwan Jintana, Sukrakanchana Praornsuda, Kanabkaew Cheeraya, Le Cœur Sophie, Lallemant Marc et Jourdain Gonzague (2008) « Severe complications associated with the concomitant use of protease inhibitors and drugs bought over-the-counter » (communication orale), présenté à 12th National AIDS Conference, Bangkok.
  • Collins Intira, Cairns John, Jaffar Shabbar, Pagdi Karin, Ngampiyasakul Chaiwat, Layangool Prapaisri, Borkird Thitiporn, Na-Rajsima Sathaporn, Wanchaitanawong Vanichaya, Le Cœur Sophie et Lallemant Marc (2011) « Cost of antiretroviral therapy in perinatally HIV infected children and factors associated high cost: an observational cohort study in Thailand » (poster), présenté à 15th International Workshop on HIV Observational Databases, Prague.

  • Collins Intira, Cairns John, Jourdain Gonzague, Fregonese Federica, Nantarukchaikul Maneeratn, Lertpienthum Narong, Wannarit Pornpun, Attavinijtrakarn Pornsawan, Layangool Prapaisri, Le Cœur Sophie et Lallemant Marc (2012) « Hospitalization trends, costs, and risk factors in HIV-infected children on antiretroviral therapy », AIDS (London, England), 26 (15) (septembre 24), p. 1943-1952. DOI : 10.1097/QAD.0b013e328357f7b9.
    Résumé : OBJECTIVE To assess hospitalization trends in HIV-infected children on antiretroviral therapy (ART) in Thailand, an important indicator of morbidity, ART effectiveness, and health service utilization. DESIGN Prospective observational cohort METHOD Children initiating ART in 1999-2009 were followed in 40 public hospitals. Hospitalization rate per 100 person-years were calculated from ART initiation to last follow-up/death. Costs to the healthcare provider were calculated using WHO inpatient estimates for Thailand. Zero-inflated Poisson models were used to examine risk factors for early (<12 months of ART) and late hospitalization (≥12 months) and frequency of admissions. RESULTS A total of 578 children initiated ART, median follow-up being 64 months [interquartile range (IQR) 43-82]; 211 (37%) children were hospitalized with 451 admissions. Hospitalization rates declined from 63 per 100 person-years at less than 6 months to approximately 10 per 100 person-years after 2 years of ART, and costs fell from $35 per patient-month to under $5, respectively. Age less than 2 years, US Centers of Disease Control and Prevention stage B/C, and stunting at ART initiation were associated with early hospitalization. Among those hospitalized, baseline CD4 cell percentage less than 5%, wasting, initiation on dual therapy, late calendar year, and female sex were associated with higher incidence of early admissions (P <0.02). There were no predictors of late hospitalization, although previous hospitalization in less than 12 months of ART was associated with three times higher incidence of late admissions (P < 0.0001). CONCLUSION One in three children required hospitalization after ART. Admissions were highest in the first year of therapy and rapidly declined thereafter. Young age, advanced disease stage, and stunting at baseline were predictive of early hospitalization. Treatment initiation before disease progression would likely reduce hospitalization and alleviate demands on healthcare services.


  • Collins Intira, Cairns John, Le Cœur Sophie, Pagdi Karin, Ngampiyasakul Chaiwat, Layangool Prapaisri, Borkird Thitiporn, Na-Rajsima Sathaporn, Wanchaitanawong Vanichaya, Jourdain Gonzague et Lallemant Marc (2013) « Five-Year Trends in Antiretroviral Usage and Drug Costs in HIV-Infected Children in Thailand », Journal of Acquired Immune Deficiency Syndromes (JAIDS), 64 (1), p. 95-102. DOI : 10.1097/QAI.0b013e318298a309. http://www.ncbi.nlm.nih.gov/pubmed/23945253.

  • Collins Intira, Cairns John, Ngo-Giang-Huong Nicole, Sirirungsi Wasna, Leechanachai Pranee, Le Cœur Sophie, Samleerat Tanawan, Kamonpakorn N, Mekmullica Jutarat, Jourdain Gonzague et Lallemant Marc (2014) « Cost-effectiveness of early infant HIV diagnosis of HIV-exposed infants and immediate antiretroviral therapy in HIV-infected children under 24 months in Thailand », PLoS One, 14 (9). DOI : 10.1371/journal.pone.0091004.

  • Collins Intira, Jourdain Gonzague, Hansudewechakul Rawiwan, Kanjanavanit Suparat, Hongsiriwon Suchat, Ngampiyasakul Chaiwat, Sriminiphant Somboon, Technakunakorn Pornchai, Ngo-Giang-Huong Nicole, Duong Trinh, Le Cœur Sophie, Jaffar Shabbar et Lallemant Marc (2010) « Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study », Clin Infect Dis, 51, p. 1449-57. DOI : 10.1086/657401.
    Résumé : BACKGROUND: There are scarce data on the long-term survival of human immunodeficiency virus (HIV)-infected children receiving antiretroviral therapy (ART) in lower-middle income countries beyond 2 years of follow-up. METHODS: Previously untreated children who initiated ART on meeting immunological and/or clinical criteria were followed in a prospective cohort in Thailand. The probability of survival up to 5 years from initiation was estimated using Kaplan-Meier methods, and factors associated with mortality were assessed using Cox regression analyses. RESULTS: Five hundred seventy-eight children received ART; of these, 111 (19.2%) were followed since birth. At start of ART (baseline), the median age was 6.7 years, 128 children (22%) were aged <2 years, and the median CD4 cell percentage was 7%. Median duration of follow-up was 53 months; 42 children (7%) died, and 38 (7%) were lost to follow-up. Age <12 months, low CD4 cell percentage, and low weight-for-height z score at ART initiation were independently associated with mortality (P < .001). The probability of survival among infants aged <12 months at baseline was 84.3% at 1 year and 76.7% at 5 years of ART, compared with 95.7% and 94.8%, respectively, among children aged >/=1 year. Low CD4 cell percentage and wasting at baseline had a strong association with mortality among older children but weak or no association among infants. CONCLUSIONS: Children who initiated ART as infants after meeting immunological and/or clinical criteria had a high risk of mortality which persisted beyond the first year of therapy. Among older children, those with severe wasting or low CD4 cell percentage at treatment initiation were at high risk of mortality during the first 6 months of therapy. These findings support the scale-up of early HIV diagnosis and immediate treatment in infants, before advanced disease progression in older children.
    Mots-clés : Anti-HIV Agents/ therapeutic use, Antiretroviral Therapy, Highly Active, Child, Child, Preschool, Cohort Studies, Female, Follow-Up Studies, HIV Infections/ drug therapy/ mortality, Humans, Infant, Male, Prospective Studies, Survival Analysis, Thailand, Time Factors.
  • Collins Intira, Le Cœur Sophie, Jourdain Gonzague, Ngo-Giang-Huong Nicole, Na-Rajsima Sathaporn, Akarathum Noppadon, Wanchaitanawong Vanichaya, Lucksanapisitkul Paiboon, Sutthipong C., Kanshana Siriporn, Lallemant Marc et Program for HIV Prevention and Treatment (PHPT) (2009) « Long Term Survival of Children on Antiretroviral Therapy (ART) in Thailand: Birth and Referred Cohorts. » (poster), présenté à 13th International Workshop on HIV Observational Databases, Lisbonne.
  • Collins Intira, Le Cœur Sophie, Jourdain Gonzague, Ngo-Giang-Huong Nicole, Na-Rajsima Sathaporn, Akarathum Noppadon, Wanchaitanawong Vanichaya, Lucksanapisitkul Paiboon, Sutthipong C., Lertpienthum Narong, Henpraserttae Samoejai, Thanasiri Pimpraphai, Srirojana Sakulrat et Lallemant Marc (2008) « Long Term Survival of Children on Antiretroviral Therapy (ART) in Thailand » (communication orale), présenté à 12th National AIDS Conference, Bangkok.
  • Collins Intira, Le Cœur Sophie, Jourdain Gonzague, Ngo-Giang-Huong Nicole, Na-Rajsima Sathaporn, Akarathum Noppadon, Wanchaitanawong Vanichaya, Lucksanapisitkul Paiboon, Sutthipong C., Lertpienthum Narong, Henpraserttae Samoejai, Thanasiri Pimpraphai, Srirojana Sakulrat et Lallemant Marc (2009) « Long Term Survival of Children on Highly Active Antiretroviral Therapy (HAART) in Thailand » (poster P21), présenté à 1st International Workshop on HIV Pediatrics, Cape Town (Afrique du Sud).
  • Collins Intira, Ngo-Giang-Huong Nicole, Jourdain Gonzague, Chanta C., Puangsombat Achara, Kwanchaipanich Ratchanee, Bunjongpak Suthunya, Cressey Tim R., Le Cœur Sophie, Jaffar Shabbar et Lallemant Marc (2011) « Long-term virologic response to highly active antiretroviral therapy (HAART) in HIV-infected children in Thailand: up to 6-years of follow up » (poster), présenté à 15th International Workshop on HIV Observational Databases, Prague.
  • Collins Intira, Ngo-Giang-Huong Nicole, Jourdain Gonzague, Chanta C., Puangsombat Achara, Kwanchaipanich Ratchanee, Bunjongpak Suthunya, Cressey Tim R., Le Cœur Sophie, Jaffar Shabbar et Lallemant Marc (2013) « Long-term immune response in HIV-infected children receiving highly active antiretroviral therapy in Thailand: outcomes at 7-years » (communication orale), présenté à 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), Kuala Lumpur.
  • Culhane-Pera Kathleen, Kunstadter Peter, Thawsirichuchai Rasamee, Yangyernkun Wirachon, Cha’taw Lakela, Ayuman S, Kunstadter A, Chailoet Sanupong, A’pa S, Klongdachonkiri P et Le Cœur Sophie (2013) « Barriers to Pregnancy-related HIV Services and PMTCT Amongst Hmong in Northern Thailand » (communication orale), présenté à 7th IAS Conference on HIV Pathogenesis IAS, Treatment and Prevention, Kuala Lumpur.

  • Duong Trinh, Jourdain Gonzague, Ngo-Giang-Huong Nicole, Le Cœur Sophie, Kantipong Pacharee, Buranabanjasatean Sudanee, Leenasirimakul Prattana, Ariyadej Sriprapar, Tansuphasawasdikul Somboon, Thongpaen Suchart et Lallemant Marc (2012) « Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand », PloS one, 7 (8), p. e43375. DOI : 10.1371/journal.pone.0043375.
    Résumé : BACKGROUND Data on determinants of long-term disease progression in HIV-infected patients on antiretroviral therapy (ART) are limited in low and middle-income settings. METHODS Effects of current CD4 count, viral load and haemoglobin and diagnosis of AIDS-defining events (ADEs) after start of combination ART (cART) on death and new ADEs were assessed using Poisson regression, in patient aged ≥ 18 years within a multi-centre cohort in Thailand. RESULTS Among 1,572 patients, median follow-up from cART initiation was 4.4 (IQR 3.6-6.3) years. The analysis of death was based on 60 events during 6,573 person-years; 30/50 (60%) deaths with underlying cause ascertained were attributable to infections. Analysis of new ADE included 192 events during 5,865 person-years; TB and Pneumocystis jiroveci pneumonia were the most commonly presented first new ADE (35% and 20% of cases, respectively). In multivariable analyses, low current CD4 count after starting cART was the strongest predictor of death and of new ADE. Even at CD4 above 200 cells/mm(3), survival improved steadily with CD4, with mortality rare at ≥ 500 cells/mm(3) (rate 1.1 per 1,000 person-years). Haemoglobin had a strong independent effect, while viral load was weakly predictive with poorer prognosis only observed at ≥ 100,000 copies/ml. Mortality risk increased following diagnosis of ADEs during cART. The decline in mortality rate with duration on cART (from 21.3 per 1,000 person-years within first 6 months to 4.7 per 1,000 person-years at ≥ 36 months) was accounted for by current CD4 count. CONCLUSIONS Patients with low CD4 count or haemoglobin require more intensive diagnostic and treatment of underlying causes. Maintaining CD4 ≥ 500 cells/mm(3) minimizes mortality. However, patient monitoring could potentially be relaxed at high CD4 count if resources are limited. Optimal ART monitoring strategies in low-income settings remain a research priority. Better understanding of the aetiology of anaemia in patients on ART could guide prevention and treatment.
    Mots-clés : Adult, Anti-HIV Agents, CD4-Positive T-Lymphocytes, Cohort Studies, Disease Progression, Female, Follow-Up Studies, HIV infections, Humans, Immunosuppression, Male, Multivariate Analysis, Poisson Distribution, Risk, Thailand, Viral Load.
  • Duracinsky Martin, Acquadro Catherine, Herrmann Susan, Berzins Baiba, Le Cœur Sophie, Ban Ban, Kohli Rewa, Ferro Do Lago R. et Chassany Olivier (2008) « International development of a new health-related quality of life questionnaire specific to HIV/AIDS » (poster n° THPE0813), présenté à XVIIe Conference internationale sur le Sida, Mexique.
  • Duracinsky Martin, Acquadro Catherine, Herrmann Susan, Le Cœur Sophie, Berzins Baiba, Kohli Rewa, Ban Boroath, Sow Papa Salif, Diop Mar Ibrahima et Chassany Olivier (2008) « Simultaneous Development In 9 Countries Of A New Health-Related Quality Of Life Questionnaire Specific to HIV/AIDS » (communication orale), présenté à 15th Annual Conference, International Society for Quality of Life Research, Montevideo.

  • Duracinsky Martin, Herrmann Susan, Berzins Baiba, Armstrong Andrew R., Kohli Rewa, Le Cœur Sophie, Diouf Assane, Fournier Isabelle, Schechter Mauro et Chassany Olivier (2012) « The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV/AIDS », J Acquir Immune Defic Syndr, 59, p. 498-505. DOI : 10.1097/QAI.0b013e318245cafe.
    Résumé : OBJECTIVES: Health-related quality of life (HRQL) is an important outcome in HIV/AIDS infection and treatment. However, most existing HIV-HRQL instruments miss important issues (eg, sleeping problems, lipodystrophy). They were developed before highly active antiretroviral therapy (pre-HAART), and in a single language. We sought to develop a contemporary HIV-HRQL instrument (PROQOL-HIV) in multiple languages that accounts for HAART treatment and side effects. This article details the 3-stage content validation phase of PROQOL-HIV. METHODS: In stage 1, we developed a conceptual model of HIV-HRQL and questionnaire item bank from thematic analysis of 152 patient interviews conducted simultaneously across 9 countries. In stage 2, pilot items were selected by an expert panel to form the pilot instrument. Stage 3 involved linguistic validation and harmonization of selected items to form an equivalent instrument in 9 target languages. RESULTS: Analysis of 3375 pages of interview text revealed 11 underlying themes: general health perception, social relationships, emotions, energy/fatigue, sleep, cognitive functioning, physical and daily activity, coping, future, symptoms, and treatment. Seven issues new to HIV-HRQL measurement were subsumed by these themes: infection fears, future concerns, satisfaction with care, self-esteem problems, sleep problems, work disruption, and treatment issues. Of the 442 theme-related items banked, 70 items met the retention criteria and formed the pilot PROQOL-HIV instrument. CONCLUSIONS: HIV patients across 11 countries attributed a wide range of physical, mental, and social issues to their condition, many of which were not measured by existing HIV-HRQL instruments. The pilot PROQOL-HIV instrument captures these issues, is sensitive to sociocultural context, disease stage, and HAART.
    Mots-clés : Activities of Daily Living, Adult, Female, Health Status, HIV Infections/ psychology, Humans, Male, Middle Aged, Pilot Projects, Psychometrics, Quality of Life, Questionnaires, Reproducibility of Results, Severity of Illness Index.
  • Duracinsky Martin, Lalanne Christophe, Acquadro Catherine, Herrmann Susan, Berzins Baiba, Le Cœur Sophie, Diouf Assane, Fournier Isabelle, Lau Joseph Tak, Schechter Mauro et Chassany Olivier (2009) « Validation of the PROQOL-HIV Questionnaire in light of cross-cultural differences from 5 continents » (communication orale), présenté à International Society for Pharmacoeconomics and Outcomes Research, 12th Annual European Congress, Paris.

  • Duracinsky Martin, Lalanne Christophe, Le Cœur Sophie, Herrmann Susan, Berzins Baiba, Armstrong Andrew R., Lau Joseph Tak, Fournier Isabelle et Chassany Olivier (2012) « Psychometric validation of the PROQOL-HIV questionnaire, a new health-related quality of life instrument-specific to HIV disease », J Acquir Immune Defic Syndr, 59, p. 506-15. DOI : 10.1097/QAI.0b013e31824be3f2.
    Résumé : OBJECTIVES: This study reports the psychometric validation of a new HIV/AIDS-specific health-related quality of life (HRQL) questionnaire, the Patient Reported Outcomes Quality of Life-HIV. The instrument was developed simultaneously across Europe, North and South America, Africa, Asia, and Australia to assess multidimensional quality of life impairments in the era of highly active antiretroviral therapy. METHOD: A cross-sectional study was performed in 8 countries. The pilot 70-item questionnaire was co-administered with the HIV symptoms index, the EQ-5D and Medical Outcomes Study-HIV questionnaires. Demographic and biomedical data were collected. After item analysis and reduction, convergent discriminant concurrent validity and known-group validity were examined. Internal consistency and reliability scores were assessed using Cronbach alpha and intraclass correlation. RESULTS: The final sample of 791 patients was composed of 64% males (median age: 41 years, HIV diagnosis = 5 years), 13.8% were treatment naive. Item reduction yielded a 43-item form surveying 8 dimensions and 1 global health item that showed good convergent and discriminant validity and reliability (98% scaling success; Cronbach alphas 0.77-0.89). Correlations with EQ-5D and Medical Outcomes Study-HIV complied with concurrent validity expectations; likewise, correlations against the number of self-reported symptoms and depression showed good support for criterion validity. A test-retest study on French patients (n = 34) showed temporal stability (intraclass correlation coefficient = 0.86). Significant and meaningful differences of HRQL scores between countries were found. CONCLUSIONS: The Patient Reported Outcomes Quality of Life-HIV questionnaire is a valid and reliable instrument for assessing HRQL specific to HIV disease in different cultures and healthcare systems.
    Mots-clés : Adult, Cross-Sectional Studies, Female, Health Status, HIV Infections/ psychology, Humans, Male, Middle Aged, Psychometrics, Quality of Life, Questionnaires/ standards, Reproducibility of Results.
  • Duracinsky Martin, Sow Papa Salif, Diouf Assane, Cilote Vannina, Acquadro Catherine, Le Cœur Sophie, Herrmann Susan, Fournier Isabelle, Barbosa Regina Maria, Kholi Rewa, Segeral Olivier et Chassany Olivier (2008) « Development of the PROQOL-HIV Questionnaire, a new Health-Related Quality of life questionnaire specific to HIV/AIDS – Senegal and international study » (communication orale), présenté à 15th International Conference on AIDS and STIs in Africa (ICASA), Dakar.


  • Fregonese Federica, Collins Intira, Jourdain Gonzague, Le Cœur Sophie, Cressey Tim R., Ngo-Giang-Huong Nicole, Banchongkit Sukit, Chutanunta Apichat, Techapornroong Malee et Lallemant Marc (2012) « Predictors of 5-Year Mortality in HIV-Infected Adults Starting Highly Active Antiretroviral Therapy in Thailand », J Acquir Immune Defic Syndr, 60, p. 91-98. DOI : 10.1097/QAI.0b013e31824bd33f. http://www.ncbi.nlm.nih.gov/pubmed/22293548.
    Résumé : OBJECTIVE:: To estimate the early and long-term mortalities and associated risk factors in adults receiving highly active antiretroviral therapy (HAART) in Thailand. DESIGN:: A prospective observational cohort study. METHODS:: Previously untreated adults starting HAART in 2002-2009 were followed-up in 43 public hospitals. Kaplan-Meier probability of survival was estimated up to 5 years of therapy. Factors associated with early (</=6 months) and long-term (>6 months) mortalities were assessed using Cox regression analyses. RESULTS:: A total of 1578 adults received HAART (74% women; median age, 33 years; CD4 cell count, 124/mL), with a median follow-up of 50 months (interquartile range, 41-66). Eighty-nine patients (6%) died (37 occurred </=6 months and 52 occurred >6 months) and 183 (12%) were lost to follow-up. Probability of survival [95% confidence interval (CI)] was 97.5% (96.7% to 98.2%) at 6 months, 96.6% (95.6% to 97.4%) at 1 year, and 93.5% (91.9% to 94.8%) at 5 years. Probability of being alive and on follow-up was 80.8% (78.5% to 82.8%) at 5 years. Early mortality was associated with anemia [adjusted hazard ratio (aHR) 3.6, 95% CI: 1.7 to 7.5] and low CD4 count (aHR 1.6, 95% CI: 1.1 to 2.2 per 50 cells decrease) at treatment initiation. Long-term mortality was associated with persistent anemia (aHR 4.9, 95% CI: 2.1 to 11.6), CD4 increase from baseline <50 cells per cubic millimeter (aHR 3.1, 95% CI: 1.6 to 5.7), and viral load >1000 copies per milliliter (aHR 2.8, 95% CI: 1.3 to 6.1) at 6 months of HAART; male gender; and calendar year of enrollment. CONCLUSIONS:: Early mortality was associated with anemia and severe immunosuppression at initiation of therapy. Long-term mortality was associated with persistent anemia, CD4 count increase, and virological response at 6 months of therapy over baseline characteristics, highlighting the importance of laboratory monitoring.
  • Fregonese Federica, Collins Intira, Jourdain Gonzague, Le Cœur Sophie, Cressey Tim R., Ngo-Giang-Huong Nicole, Banchongkit Sukit, Chutanunta Apichat, Techapornroong Malee, Lallemant Marc et Program for HIV Prevention and Treatment (PHPT) (2011) « Long Term Survival of HIV-infected Adults Starting Highly Active Antiretroviral Therapy (HAART) in Thailand: Risk Factors for Early and Late Mortality » (poster n° 561), présenté à 18th Conference on Retroviruses and Opportunistic Infections, Boston.
  • Fregonese Federica, Collins Intira, Jourdain Gonzague, Le Cœur Sophie, Cressey Tim R., Ngo-Giang-Huong Nicole, Banchongkit Sukit, Chutanunta Apichat, Techapornroong Malee, Lallemant Marc et Program for HIV Prevention and Treatment (PHPT) (2011) « Survival at 5 years of HIV-infected adults starting highly active antiretroviral therapy (HAART) in Thailand: risk factors for early and long-term mortality » (communication orale), présenté à 13th National AIDS Seminar "AIDS Rights is Human Rights, Join to Protect and Respond", Nonthaburi.

  • Gonzague Jourdain, Le Cœur Sophie, Ngo-Giang-Huong Nicole, Traisaithit Patrinee, Cressey Tim R., Fregonese Federica, Leurent Baptiste, Collins Intira, Jeannie Techapornroong Malee, Banchongkit Sukit, Buranabanjasatean Sudanee, Halue Guttiga et Nilmanat Ampaipith (2013) « Switching HIV Treatment in Adults Based on CD4 Count Versus Viral Load Monitoring: A randomized, Non-Inferiority Trial in Thailand », PLoS Medicine, 10 (8). DOI : 10.1371/journal.pmed.1001494.

  • Jourdain Gonzague, Collins Intira et Le Cœur Sophie (2009) « Prevention of Mother-to-Child Transmission as an Entry Point to Care and Treatment », in From the Ground Up: Building Comprehensive HIV/AIDS Care Programs in Resource-Limited Settings, éd. par Richard Marlink et Sarah Teitelman, Washington, DC : Elizabeth Glaser Pediatric AIDS Foundation, p. 795-802. http://ftguonline.org/ftgu-232/index.php/ftgu/article/download/2011/4019.
  • Jourdain Gonzague, Le Cœur Sophie, Ngo-Giang-Huong Nicole, Cressey Tim R., Collins Intira, Hansudewechakul Rawiwan, Kanjanavanit Suparat, Ngampiyasakul Chaiwat, Hongsiriwon Suchat, Layangool Prapaisri, Traisathit Patrinee et Lallemant Marc (2009) « A Comprehensive Program to Ensure Optimal Antiretroviral Treatment in Children in Thailand: the PHPT Observational Cohort » (Poster P44), présenté à 1st International Workshop on HIV Pediatrics, Cape Town (Afrique du Sud).
  • Jourdain Gonzague, Ngo-Giang-Huong Nicole, Le Cœur Sophie, Bowonwatanuwong Chureeratana, Kantipong Pacharee, Leechanachai Pranee, Ariyadej Surabon, Leenasirimakul Prattana, Lallemant Marc et Perinatal HIV Prevention Trial Group (2008) « Long term clinical and therapeutic outcome of nevirapine based antiretroviral treatment in women who have been exposed to intra labor single dose nevirapine for perinatal HIV transmission prevention » (poster 12C1194), présenté à 12th International Workshop on HIV Observational Databases, Malaga (Espagne).
  • Jourdain Gonzague, Ngo-Giang-Huong Nicole, Le Cœur Sophie, Bowonwatanuwong Chureeratana, Kantipong Pacharee, Yuthavisuthi Prapap, Prommas P., Halue Guttiga, Achalapong Jullapong, Lallemant Marc et Program for HIV Prevention and Treatment (PHPT) (2009) « 4-Year Clinical and Therapeutic Consequences of Intrapartum single-dose nevirapine for the prevention of perinatal HIV in women who subsequently initiated a nevirapine-based ART » (poster n° 954), présenté à 16th Conference on Retroviruses and Opportunistic Infections, Montréal.
  • Jourdain Gonzague, Ngo-Giang-Huong Nicole, Le Cœur Sophie, Traisathit Patrinee, Barbier Sylvaine, Techapornroong Malee, Banchongkit Sukit, Buranabanjasatean Sudanee, Halue Guttiga, Lallemant Marc et PHPT-3 study group (2011) « PHPT-3: A Randomized Clinical Trial Comparing CD4 versus Viral Load (VL) Antiretroviral Therapy Monitoring/Switching Strategies in Thailand » (communication orale), présenté à 18th Conference on Retroviruses and Opportunistic Infections, Boston.
  • Jourdain Gonzague, Ngo-Giang-Huong Nicole, Le Cœur Sophie, Traisathit Patrinee, Barbier Sylvaine, Techapornroong Malee, Banchongkit Sukit, Buranabanjasatean Sudanee, Halue Guttiga, Lallemant Marc et PHPT-3 study group (2011) « PHPT-3: A Randomized Clinical Trial Comparing CD4 versus Viral Load (VL) Antiretroviral Therapy Monitoring/Switching Strategies in Thailand » (communication orale), présenté à 13th National AIDS Seminar "AIDS Rights is Human Rights, Join to Protect and Respond", Nonthaburi.
  • Kunstadter Peter, Lallemant Marc, Le Cœur Sophie, Kanabkaew Cheeraya, Chalermpantmetagul Suwalai, Collins Intira et Lazarus Margery (2011) « Program for HIV Prevention and Treatment (PHPT): Evolution of an International-Interdisciplinary Organization for Applied Clinical and Social Research in Thailand » (communication orale), présenté à Annual conference of the Society for Applied Anthropology, Seattle.
  • Kunstadter Peter, Thawsirichuchai Rasamee, Yangyernkun Wirachon, Kunstadter A, Chailert S, Culhane-Pera Kathleen et Le Cœur Sophie (2013) « Disparities in access to HIV-related health services: ethnic minorities and trans-border migrants » (communication orale), présenté à 11th International Congress on AIDS in Asia and the Pacific, Bangkok.

  • Lalanne Christophe, Armstrong Andrew R., Herrmann Susan, Le Cœur Sophie, Carrieri Patrizia, Chassany Olivier et Duracinsky Martin (2014) « Psychometric assessment of health-related quality of life and symptom experience in HIV patients treated with antiretroviral therapy », Quality of Life Research (décembre 7). DOI : 10.1007/s11136-014-0880-8.


  • Lallemant Camille, Halembokaka Gaston, Baty Gaelle, Ngo-Giang-Huong Nicole, Barin Francis et Le Cœur Sophie (2010) « Impact of HIV/Aids on Child Mortality before the Highly Active Antiretroviral Therapy Era: A Study in Pointe-Noire, Republic of Congo », Journal of Tropical Medicine, 2010, p. 6. DOI : 10.1155/2010/897176. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933897/pdf/JTM2010-897176.pdf.
    Résumé : Few studies have documented the contribution of HIV/AIDS to mortality among children under 15 years. From June 30 to October 19, 2001, all child deaths (n = 588) registered to the morgue and/or hospitals of the city of Pointe-Noire, Congo, were investigated using a combined approach including an interview of relatives and postmortem clinical and biological HIV diagnosis. Twenty-one percent of children were HIV positive, while 10.5% of deaths were attributed to AIDS. The most common causes of death in HIV-infected children were pneumonia (30%), pyrexia (22%), diarrhoea (16%) and wasting syndrome (16%). Infant mortality rate was estimated 6.3 times higher in children born to HIV-infected mothers compared to HIV-uninfected mothers. This study provides a direct measure of HIV/AIDS as impact on child mortality using a rapid and reliable method. A significant number of deaths could be prevented if HIV infection was diagnosed earlier and infants were provided with antiretroviral treatments.
  • Lallemant Marc, Jourdain Gonzague, Ngo-Giang-Huong Nicole, Le Cœur Sophie, Cressey Tim R., Puangsombat Achara, Phanomcheong Siriluk, Klinbuayaem Virat, Pattarakulwanich Somsak, Koetsawang Suporn et PHPT-5 Team (2011) « Maternal and infant nevirapine versus infant only nevirapine, or maternal lopinavir/ritonavir in addition to standard zidovudine prophylaxis to prevent perinatal HIV in Thailand » (poster n° 741), présenté à 18th Conference on Retroviruses and Opportunistic Infections, Boston.

  • Lallemant Marc, Ngo-Giang-Huong Nicole, Jourdain Gonzague, Traisathit Patrinee, Cressey Tim R., Collins Intira, Jarupanich Tapnarong, Sukhumanant Thammanoon, Achalapong Jullapong, Sabsanong Prapan, Chotivanich Nantasak, Winiyakul Narong, Ariyadej Surabon, Kanjanasing Annop, Ratanakosol Janyaporn, Hemvuttiphan Jittapol, Kengsakul Karun, Wannapira Wiroj, Sittipiyasakul Veerachai, Pornkitprasarn Witaya, Liampongsabuddhi Prateung, McIntosh Kenneth, Van Dyke Russell B., Frenkel Lisa M., Koetsawang Suporn, Le Cœur Sophie et Kanshana Siriporn (2010) « Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine », Clin Infect Dis, 50, p. 898-908. DOI : 10.1086/650745.
    Résumé : BACKGROUND: Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine are essential components of programs to prevent mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings. The persistence of nevirapine in the plasma for 3 weeks postpartum risks selection of resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTIs). We hypothesized that a 1-month zidovudine-didanosine course initiated at the same time as single-dose nevirapine (sdNVP) would prevent the selection of nevirapine-resistance mutations. METHODS: HIV-infected pregnant women in the PHPT-4 cohort with CD4 cell counts >250 cells/mm3 received antepartum zidovudine from the third trimester until delivery, sdNVP during labor, and a 1-month zidovudine-didanosine course after delivery. These women were matched on the basis of baseline HIV load, CD4 cell count, and duration of antepartum zidovudine to women who received sdNVP in the PHPT-2 trial (control subjects). Consensus sequencing and the more sensitive oligonucleotide ligation assay were performed on samples obtained on postpartum days 7-10, 37-45, and 120 (if the HIV load was >500 copies/mL) to detect K103N/Y181C/G190A mutations. RESULTS: The 222 PHPT-4 subjects did not differ from matched control subjects in baseline characteristics except for age. The combined group median CD4 cell count was 421 cells/mm3 (interquartile range [IQR], 322-549 cells/mm3), the median HIV load was 3.45 log10 copies/mL (IQR, 2.79-4.00 log10 copies/mL), and the median duration of zidovudine prophylaxis was 10.4 weeks (IQR, 9.1-11.4 weeks). Using consensus sequencing, major NNRTI resistance mutations were detected after delivery in 0% of PHPT-4 subjects and 10.4% of PHPT-2 controls. The oligonucleotide ligation assay detected resistance in 1.8% of PHPT-4 subjects and 18.9% of controls. Major NNRTI resistance mutations were detected by either method in 1.8% of PHPT-4 subjects and 20.7% of controls (P < .001). CONCLUSIONS: A 1-month postpartum course of zidovudine plus didanosine prevented the selection of the vast majority of NNRTI resistance mutations.
    Mots-clés : Adult Anti-HIV Agents, adverse effects, Didanosine/adverse effects/therapeutic use, DNA Viral Load, drug effects/isolation & purification, Drug Resistance, drug therapy, Humans Ligase Chain Reaction Mutation, Lymphocyte Count, Missense Nevirapine/adverse effects/therapeutic use, Postpartum Period Pregnancy RNA, therapeutic use CD4, Viral Female HIV Infections, Viral/genetics Sequence Analysis, virology HIV-1, Young Adult, Zidovudine/adverse effects/therapeutic use.

  • Larmarange Joseph et Le Cœur Sophie (2013) The current situation of the HIV/AIDS epidemic 2013, Information sheet, Paris : Ined, 3 p. http://www.ined.fr/en/everything_about_population/news/aids_2013/.
    Résumé : According to UNAIDS estimates for the year 2012, 35.3 million persons are infected with the HIV virus worldwide and there were 2.3 million new infections and 1.6 million deaths that year. Sub-Saharan Africa is by far the hardest-hit region, with 25 million people infected, followed by South and Southeast Asia, with a combined total of 4.8 million. The burden of the epidemic in a given country is expressed by the proportion of infected persons among the entire adult population, or prevalence. Prevalence varies greatly by country; the highest rates are in Southern Africa; in some Southern African countries over 20% of the adult population is infected.

  • Larmarange Joseph et Le Cœur Sophie (2013) La situation de l’épidémie VIH/Sida en 2013, Fiche d'actualité, Paris : Ined, 3 p. http://www.ined.fr/fr/tout_savoir_population/fiches_actualite/vih_sida_2013/.
    Résumé : Dans son bilan pour l'année 2012, l'ONUSIDA estime à 35,3 millions le nombre de personnes infectées par le VIH dans le monde, avec 2,3 millions de nouvelles infections et 1,6 million de décès dans l'année. L'Afrique sub-saharienne est de loin la région du monde la plus touchée (25 millions de personnes infectées), suivie par l'Asie du Sud et du Sud-Est (4,8 millions). Le poids de l'épidémie dans un pays s'exprime par la proportion de personnes infectées dans l'ensemble de la population adulte (ou prévalence). Elle varie fortement d'un pays à l'autre, le maximum étant atteint en Afrique australe : plus de 20 % de la population adulte dans certains pays !

  • Larmarange Joseph et Le Cœur Sophie (2008) La situation de l’épidémie VIH/Sida, Fiche d'actualité (5), Paris : Ined, 3 p. http://www.ined.fr/fr/tout_savoir_population/fiches_actualite/sida/.
    Résumé : La découverte en 1983 du virus du sida (Virus de l'immunodéficience humaine ou VIH) par deux chercheurs français de l'Institut Pasteur, Françoise Barré-Sinoussi et Luc Montagnier vient d'être couronnée par l'attribution du prix Nobel de médecine 2008. Vingt-cinq ans après cette découverte majeure, où en est l'épidémie de VIH/sida ?
  • Lautissier Adeline, Kunstadter Peter, Lallemant Marc, Chaiwan Jintana et Le Cœur Sophie (2011) « Crossroads of migration and HIV/AIDS policies: the role of Civil Society Organizations (CSOs) in Improving Access to HIV Prevention and Treatment for Migrants and Ethnic Minorities in Thailand. Beyond State protection: are CSOs bridging the gap? » (communication orale), présenté à Annual conference of the Society for Applied Anthropology, Seattle.
  • Lazarus Margery, Kunstadter Peter, Le Cœur Sophie, Kanabkaew Cheeraya, Thawsirichuchai R., Chalermpantmetagul Suwalai, Lallemant Marc et Visrutaratna S. (2011) « Borders of Antiretroviral Access: HIV/AIDS Care for Trans-border Migrants in Northern Thailand » (communication orale), présenté à Annual conference of the Society for Applied Anthropology, Seattle.
  • Le Cœur Sophie (2008) « Gender differences in access to HIV testing and treatment » (communication orale), présenté à International Symposium ”Treating People with HIV: Research, Implementation, Public Health”, Chiang Mai.
  • Le Cœur Sophie (2013) « The epidemiological/demographic point of view : Assessment of Health-Related Quality of Life (HRQoL) in HIV/AIDS - Why and How? » (communication orale), présenté à 7th IAS Conference on HIV Pathogenesis IAS, Treatment and Prevention, Kuala Lumpur.
  • Le Cœur Sophie (2010) « Introduction de l'atelier » (communication orale), présenté à Atelier Living with ARV (LIWA): Results, Teens with ARV (TEEWA): Plans, Chiang Mai.
  • Le Cœur Sophie (2009) « Social Science studies in Thailand » (communication orale), présenté à Journées scientifiques des sites ANRS en Asie du sud-est, Ho Chi Minh Ville.
  • Le Cœur Sophie (2011) « Papillomavirus et cancer du col de l'utérus », Science au Sud, le journal de l'IRD, 60, p. 10.

0 | 50

--- Exporter la sélection au format